Quantcast

Latest C-Raf Stories

2013-08-13 11:35:26

Neural stem cells transplanted into tumor-bearing rats can hinder tumor cell growth and prolife-ration; however, the mechanism remains unclear. Abnormal activation of the Ras/Raf/Mek/Erk signaling cascade plays an important role in glioma. Inhibition of this aberrant activity could effectively hinder glioma cell proliferation and promote cell apoptosis. To investigate the mechanism of glioblastoma treatment by neural stem cell trans-plantation with respect to the Ras/Raf/Mek/Erk pathway, Hua...

2011-06-20 07:37:50

(Ivanhoe Newswire) -- A new study reveals a single mutation, known as BRAF V600E, occurred in every patient in a group with hairy cell leukemia, suggesting this mutation could have implications for treating the disease. According to the National Cancer Institute, hairy cell leukemia (HCL) is a cancer of the blood and bone marrow. It is a rare type of leukemia that slowly worsens or does not change at all. The disease is called "hairy" cell leukemia because the leukemia cells look "hairy" when...

2010-10-21 12:44:20

Researchers at the Institute for Research in Immunology and Cancer (IRIC) of the Universit© de Montr©al have identified a new mechanism controlling the transmission of an abnormal signal at the origin of several cancers. In an article published in the journal Cell, Marc Therrien's team explains the recent discovery of a protein complex that controls the RAS/MAPK signalling pathway, responsible for some of the deadliest cancers, including pancreatic, colon and lung cancers, and...

2010-02-24 05:00:00

CARLSBAD, Calif., Feb. 24 /PRNewswire/ -- AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has launched an expanded test panel to detect 17 B-RAF mutations for research use to enhance the understanding of B-RAF mutations. The featured four-part series in The New York Times, this week focuses on the importance of B-RAF mutations and the next generation of cancer therapies. "We congratulate Plexxikon and Roche on the dramatic success of...

2010-02-10 06:00:00

New kinase array designed for drug screening, substrate profiling and kinase interaction discovery VANCOUVER, Feb. 10 /PRNewswire/ - Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and...

2009-06-18 02:06:00

LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Florida corporation, announce the signature of an exclusive license agreement for the development and commercialization of Debio 0928, a small molecule in early preclinical development that inhibits...

2009-01-30 09:13:55

Scientists have uncovered an interesting connection between two important protein kinase signaling pathways that are associated with cancer. The research, published by Cell Press in the January 30th issue of the journal Molecular Cell, may direct new therapeutic strategies for multiple types of cancer.The protein kinase LKB1 is a known tumor suppressor and the LKB1-AMPK signaling pathway couples energy metabolism with cell growth, proliferation and survival. "Mutations in LKB1 are not...

2008-10-23 06:00:11

Exelixis, Inc. (Nasdaq:EXEL) today announced that GlaxoSmithKline (GSK) (LSE: GSK; NYSE: GSK) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844. As a result, Exelixis retains the rights to develop, commercialize, and/or license all of the compounds, subject to payment to GSK of a 3% royalty on net sales of any product incorporating XL184....

2008-10-08 09:00:12

Ardea Biosciences has announced positive data from a preclinical study of RDEA119, the company's lead mitogen-activated ERK kinase inhibitor, which showed the product candidate to be a promising investigational therapy for inflammatory diseases. According to the company, oral administration of RDEA119 was shown to significantly reduce damage to colonic tissue and disease activity in dextran sulfate sodium - induced chronic colitic mice. The beneficial effect of RDEA119 exceeded that of...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related